Business
Elevar Therapeutics' NDA Resubmission For Rivoceranib With Camrelizumab Accepted By FDA
Elevar Therapeutics' NDA Resubmission For Rivoceranib With Camrelizumab Accepted By FDA
About this update from Hlb Co., Ltd.
Elevar Therapeutics:ELEVAR THERAPEUTICS: ANNOUNCES FDA ACCEPTANCE OF NDA RESUBMISSION FOR RIVOCERANIB IN COMBINATION WITH CAMRELIZUMABELEVAR THERAPEUTICS: FDA ASSIGNED PDUFA TARGET ACTION DATE OF JULY 23, 2026